Company intelligence / Profile preview

isRed Pharma & Biotech Research

Ownership: Private
Development stage: Phase 3

Overview

The only publicly available clinical result is a Phase 4 randomized crossover pharmacokinetic study evaluating the bioequivalence of an esomeprazole injectable formulation compared to Nexium Powder for Injection in healthy adults in Taiwan. The status of this trial is listed as "unknown" and there are no published results or additional pipeline data available as of January 2025.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

esomeprazole

Phase 4

Indications: Acid reflux

Beyond the preview

Go deeper on isRed Pharma & Biotech Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isRed Pharma & Biotech Research.

Explore the full profile